{"id":642048,"date":"2023-03-10T14:56:01","date_gmt":"2023-03-10T14:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=642048"},"modified":"2023-03-10T14:56:01","modified_gmt":"2023-03-10T14:56:01","slug":"tigit-inhibitors-pipeline-constitutes-18-key-companies-continuously-working-towards-developing-20-tigit-inhibitors-treatment-therapies-analyzes-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/tigit-inhibitors-pipeline-constitutes-18-key-companies-continuously-working-towards-developing-20-tigit-inhibitors-treatment-therapies-analyzes-delveinsight_642048.html","title":{"rendered":"TIGIT Inhibitors pipeline constitutes 18+ key companies continuously working towards developing 20+ TIGIT Inhibitors treatment therapies, analyzes DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1678424581.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"TIGIT Inhibitors pipeline constitutes 18+ key companies continuously working towards developing 20+ TIGIT Inhibitors treatment therapies, analyzes DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1678424581.jpeg\" alt=\"TIGIT Inhibitors pipeline constitutes 18+ key companies continuously working towards developing 20+ TIGIT Inhibitors treatment therapies, analyzes DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>TIGIT Inhibitors pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on lymphocytes that was recently propelled under the spotlight as a major emerging target in cancer immunotherapy. TIGIT interacts with CD155 expressed on antigen\u2010presenting cells or tumor cells to down\u2010regulate T cell and natural killer (NK) cell functions. TIGIT has emerged as a key inhibitor of anti\u2010tumor responses that can hinder multiple steps of the cancer immunity cycle.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsights, &#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/tigit-inhibitors-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>TIGIT Inhibitors Competitive landscape, 2023<\/strong><\/a>&#8221; report provides comprehensive insights about 18+ companies and TIGIT Inhibitors drugs in TIGIT inhibitors Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about the TIGIT Inhibitors Competitive landscape report, click here: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/tigit-inhibitors-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>TIGIT Inhibitors Competitive Assessment<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the TIGIT Inhibitors Competitive landscape report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Leading TIGIT Inhibitors Companies working in the market are Merck Sharp &amp; Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen.<\/li>\n<li>Key TIGIT Inhibitors therapies in various stages of development include Ociperlimab+ Tislelizumab, MK-7684A, Domvanalimab+ Zimberelimab, BMS 986207, BAT-6005, AGEN 1777+ PD-1 Inhibitor, PH 804, TSRF-786-C and Others.<\/li>\n<li>In December 2021, Bio-Thera Solutions a commercial-stage pharmaceutical company announced that dosing has begun in Phase I clinical study to compare the pharmacokinetics and safety of BAT6005, a monoclonal antibody targeting TIGIT in cancer patient volunteers.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&#8217;s TIGIT Inhibitors Report covers around 200+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Assessment by TIGIT Inhibitors Product Type<\/li>\n<li>Assessment by Stage and Product Type of TIGIT Inhibitors<\/li>\n<li>Assessment by Route of Administration<\/li>\n<li>Assessment by Stage and Route of Administration of TIGIT Inhibitors<\/li>\n<li>Assessment by TIGIT Inhibitors Molecule Type<\/li>\n<li>Assessment by Stage and Molecule Type of TIGIT Inhibitors<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Emerging TIGIT Inhibitors Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<p style=\"text-align: justify;\">Some of the TIGIT Inhibitors therapies are Ociperlimab, MK-7684A (pembrolizumab\/vibostolimab), BMS 986207, BAT-6005 and Many Others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Further TIGIT Inhibitors product details are provided in the report. Download the TIGIT Inhibitors Pipeline report to learn more about the emerging TIGIT Inhibitors therapies at: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/tigit-inhibitors-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>TIGIT Inhibitors Clinical Trials and Developments<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<table style=\"width: 654px;\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td valign=\"top\">\n<p><strong>Drug\/Drug Combination<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p><strong>Company Name<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p><strong>Phase<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p><strong>Indication<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>Ociperlimab +&nbsp;&nbsp;Tislelizumab<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>BeiGene<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Phase III<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Non-small Cell Lung Cancer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>MK-7684A (pembrolizumab\/vibostolimab)<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Merck Sharp &amp; Dohme<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Phase III<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Non-Small-Cell Lung Carcinoma<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>Domvanalimab +&nbsp;&nbsp;Zimberelimab&nbsp;<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Arcus Biosciences<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Phase III<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Non-Small Cell Lung Cancer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>BMS 986207<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Bristol-Myers Squibb<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Phase II<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Non-Small Cell Lung Cancer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>BAT-6005<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Bio-Thera Solutions<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Phase I<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Locally Advanced or Metastatic Solid Tumors<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>AGEN 1777 +&nbsp;&nbsp;PD-1 Inhibitor<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Agenus<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Phase I<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Advanced Solid Tumors<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>PH 804<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Phio Pharmaceuticals<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Preclinical<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Solid Tumors<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>TSRF-786-C<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Tasrif Pharmaceutical<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Preclinical<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Cancer<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key companies in the TIGIT Inhibitors Therapeutics Market:<\/strong><\/p>\n<p style=\"text-align: justify;\">Some of the TIGIT Inhibitors Companies working in the market are Merck Sharp &amp; Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report to know in detail about the recent developments and advancements in TIGIT Inhibitors clinical trials &#8211; <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/tigit-inhibitors-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>TIGIT Inhibitors Competitive Landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\">1. TIGIT Inhibitors Pipeline Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. TIGIT Inhibitors Pipeline Report Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. TIGIT Inhibitors Pipeline: Overview<\/p>\n<p style=\"text-align: justify;\">4. Analytical Perspective In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">5. TIGIT Inhibitors Clinical Trial Therapeutics<\/p>\n<p style=\"text-align: justify;\">6. TIGIT Inhibitors Pipeline: Late Stage Products (Pre-registration)<\/p>\n<p style=\"text-align: justify;\">7. TIGIT Inhibitors Pipeline: Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">8. TIGIT Inhibitors Pipeline: Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">9. TIGIT Inhibitors Pipeline: Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">10. TIGIT Inhibitors Pipeline Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products in the TIGIT Inhibitors Pipeline<\/p>\n<p style=\"text-align: justify;\">12. Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">13. Key TIGIT Inhibitors Companies<\/p>\n<p style=\"text-align: justify;\">14. Key Products in the TIGIT Inhibitors Pipeline<\/p>\n<p style=\"text-align: justify;\">15. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">16. TIGIT Inhibitors Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">17. Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">18. Analyst Views<\/p>\n<p style=\"text-align: justify;\">19. Appendix<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report to know more about @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/tigit-inhibitors-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>TIGIT Inhibitors Drugs and Therapies<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=tigit-inhibitors-pipeline-constitutes-18-key-companies-continuously-working-towards-developing-20-tigit-inhibitors-treatment-therapies-analyzes-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=tigit-inhibitors-pipeline-constitutes-18-key-companies-continuously-working-towards-developing-20-tigit-inhibitors-treatment-therapies-analyzes-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>TIGIT Inhibitors pipeline T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on lymphocytes that was recently propelled under the spotlight as a major emerging target in cancer immunotherapy. TIGIT interacts with CD155 expressed on antigen\u2010presenting cells &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/tigit-inhibitors-pipeline-constitutes-18-key-companies-continuously-working-towards-developing-20-tigit-inhibitors-treatment-therapies-analyzes-delveinsight_642048.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-642048","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/642048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=642048"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/642048\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=642048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=642048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=642048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}